Given their high lethality, relative ease of procurement
and lack of therapeutics for clinical treatment, henipaviruses
are classified as biological safety level 4 (BSL4) pathogens and
are listed as National Institute of Allergy and Infectious Diseases
(NIAID) category C priority pathogens.